Biogen's Scangos sees potential to dominate hemophilia market
This article was originally published in Scrip
Executive Summary
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.